Details of the Drug Combinations

General Information of This Drug (ID: DMRBVHE)

Drug Name

GSK690693 DMRBVHE

Synonyms

937174-76-0; GSK690693; GSK-690693; GSK 690693; UNII-GWH480321B; (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol; CHEBI:90677; GWH480321B; 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol; 4-{2-(4-Amino-1,2,5-Oxadiazol-3-Yl)-1-Ethyl-7-[(3s)-Piperidin-3-Ylmethoxy]-1h-Imidazo[4,5-C]pyridin-4-Yl}-2-Methylbut-3-Yn-2-Ol; J-502225; C21H27N7O3

Indication

Disease Entry	ICD 11	Status	REF
Haematological malignancy	2B33.Y	Phase 1	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

7 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
GSK690693 + Trametinib	DCTUUAQ	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[2]
GSK690693 + Trametinib	DCF0ZVQ	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[2]
GSK690693 + Trametinib	DCQXD4J	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: RD)	[2]
GSK690693 + Cotellic	DC7VE8K	Cotellic	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[2]
GSK690693 + Cotellic	DCRSWNG	Cotellic	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[2]
GSK690693 + Cotellic	DCO6RGX	Cotellic	Embryonal rhabdomyosarcoma (Cell Line: RD)	[2]
GSK690693 + Mitomycin	DC5MIFB	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DrugCom(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5196).
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.